Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lapatinib plus paclitaxel as first-line therapy for ErbB2-amplified metastatic breast cancer
2005-003945-16Phase 2Completed
- Sponsor
- GSK
- Start
- Feb 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lapatinib and paclitaxel in breast cancer, sponsored by GSK. Primary endpoint: Overall tumour response rate. Started Feb 2006; status: completed.
02
Drugs
lapatinibpaclitaxel
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2005-003945-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-003945-16.